Mainline Biosciences, Inc.
🇺🇸United States
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
Early Phase 1
Withdrawn
- Conditions
- Ovary CancerAdvanced Solid TumorBreast CancerNon Small Cell Lung CancerPancreatic Neoplasms
- Interventions
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Mainline Biosciences, Inc.
- Registration Number
- NCT05465590
© Copyright 2025. All Rights Reserved by MedPath